Tryptophan hydroxylase

ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION

Retrieved on: 
Friday, May 6, 2022

Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vasoconstriction, cellular proliferation, and remodeling in the small pulmonary arteries.

Key Points: 
  • Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by vasoconstriction, cellular proliferation, and remodeling in the small pulmonary arteries.
  • These changes lead to high pulmonary arterial pressure, right heart strain, and ultimately, right heart failure and death.
  • Altavant is currently testing this mechanism of action in ELEVATE 2, a proof-of-concept Phase 2 study of rodatristat ethyl in patients with PAH.
  • Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor in Phase 2 development for patients with pulmonary arterial hypertension.

ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530

Retrieved on: 
Monday, May 2, 2022

Results of in vivo studies presented at ISHLT demonstrate that once-daily administration of aerosolized ALTA-2530 achieved distribution to the distal regions of the lung.

Key Points: 
  • Results of in vivo studies presented at ISHLT demonstrate that once-daily administration of aerosolized ALTA-2530 achieved distribution to the distal regions of the lung.
  • , Altavant's Chief Medical Officer added, "Following lung transplant, inappropriate activation of the innate immune system has been shown to drive transplant rejection.
  • ALTA-2530 is currently in preclinical development at Altavant for the treatment of BOS and chemical lung injuries.
  • Altavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases.

Altavant Sciences to Present Data Supporting Once-Daily Dosing of Rodatristat Ethyl at CHEST 2019

Retrieved on: 
Friday, October 18, 2019

Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin.

Key Points: 
  • Rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin.
  • Altavant is currently testing this mechanism of action in the ELEVATE1 proof-of-concept Phase 2a study of rodatristat ethyl in patients with pulmonary arterial hypertension (PAH).
  • Altavant Sciences is a clinical-stage biopharmaceutical company focused on elevating patient-centric drug development in rare respiratory diseases with an initial focus on pulmonary arterial hypertension (PAH).
  • Rodatristat ethyl is currently being investigated in the ELEVATE1 Phase 2a study in patients with PAH.

Lexicon Pharmaceuticals Announces Poster Presentations at the NANETS Annual Multidisciplinary NET Medical Symposium

Retrieved on: 
Wednesday, October 2, 2019

THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium (NANETS; October 3-5, Boston, MA).

Key Points: 
  • THE WOODLANDS, Texas, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from five posters highlighting XERMELO (telotristat ethyl) will be presented at the upcoming North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium (NANETS; October 3-5, Boston, MA).
  • XERMELO targets tryptophan hydroxylase, an enzyme that mediates the excess serotonin production within metastatic neuroendocrine tumor (mNET) cells.
  • Lexicon has granted Ipsen an exclusive royalty-bearing right and license to commercialize XERMELO outside of the United States and Japan.
  • Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

Altavant Sciences to Present New Rodatristat Ethyl Clinical Biomarker and Safety Findings at the ERS International Congress 2019

Retrieved on: 
Tuesday, September 24, 2019

The poster will be presented on Tuesday, October 1 at 12:50 CEST and will be available on the Publications page of the Altavant website following its presentation at the congress.

Key Points: 
  • The poster will be presented on Tuesday, October 1 at 12:50 CEST and will be available on the Publications page of the Altavant website following its presentation at the congress.
  • Rodatristat is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the body's peripheral production of serotonin.
  • Altavant is currently evaluating rodatristat ethyl in the ELEVATE1 proof-of-concept Phase 2a study in patients with PAH.
  • Rodatristat ethyl is currently being evaluated in the ELEVATE1 Phase 2 Study for patients with PAH.